Impact of Netrin-1 in the Pathophysiology of Placenta Accreta Spectrum

NCT ID: NCT04628169

Last Updated: 2024-09-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-01-01

Study Completion Date

2023-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main goal of this study is to assess the role of Netrin 1, neogenin and ZEB1 in PAS-associated invasion

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* To evaluate the immunohistochemical expression of these proteins in PAS specimens in comparison with the control placental tissues.
* To correlate their expression with the demographic parameters.
* To assess the correlation between their expression in PAS specimens.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pathophysiology of Placenta Accreta

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

group A

30 placental specimens of PAS

no intervention applied

Intervention Type OTHER

no intervention applied

group B

30 placental specimens of heaithy women with normal pregnancy

no intervention applied

Intervention Type OTHER

no intervention applied

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

no intervention applied

no intervention applied

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* PAS patients who underwent hysterectomy to allow proper pathologic grading of PAS

Exclusion Criteria

* patients with fundal and middle anterior or posterior placenta,
* pregnancy associated with morbid conditions such as hypertension, diabetes mellitus, autoimmune disease, cardiac disease, renal disease, history of anemia, blood transfusion, other blood diseases and endocrinal disease; fetal distress or intrauterine growth retardation.
* uterine scar pregnancies were excluded
Minimum Eligible Age

20 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assiut University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hanaa Mohammed Mohammed Sayed

assistant lecturer

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hanaa Mohammed Mohammed Sayed

Asyut, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

netrin-1 in placenta accreta

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.